Kinnate Biopharma Inc. (KNTE)
Kinnate Biopharma Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Francisco, CA, US. The stock last traded at $2.65, down 0.38% on the session, giving a market capitalisation of $125.0M. On trailing twelve-month figures it carries a trailing P/E of -1.10, a net margin of 0.0%. Its beta of 1.34 implies it has historically moved more than the broad market.
Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily focused on identifying and advancing small-molecule drugs that target kinase enzymes to treat cancers defined by specific genetic markers. The company's product pipeline includes: KIN-2787: An inhibitor of rapidly accelerated fibrosarcoma (RAF), currently being developed to treat patients with lung cancer, melanoma, and other forms of solid tumors. KIN-3248: A small-molecule kinase inhibitor designed to counteract cancer-associated genetic mutations in the fibroblast growth factor receptors, specifically FGFR2 and FGFR3. KIN004 Program: This program encompasses early-stage small-molecule research, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor. Established in 2018, Kinnate Biopharma Inc. maintains its headquarters in San Francisco, California. It was formerly a division of Fount Therapeutics, LLC.
Kinnate Biopharma Inc. is most often compared with the following Healthcare names: